Company: INSP
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0001609550-25-000053
Chunk: 89

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 89
---
 compensation. The measure of segment assets is reported on the balance sheet as total consolidated assets.Three Months EndedNine Months EndedSeptember 30,September 30,2025202420252024Revenue$224,501 $203,191 $642,904 $563,086 Less: (a)Cost of goods sold31,773 32,398 97,154 86,998 Research and development expense24,211 26,083 78,223 83,792 Selling, general and administrative expense (excluding advertising expense)122,464 107,111 380,619 315,997 Advertising expense36,409 23,281 82,065 72,100 Operating income9,644 14,318 4,843 4,199 Other income (b)(3,907)(6,008)(10,535)(17,618)Income taxes3,619 1,829 6,046 3,532 Segment net income9,932 18,497 9,332 18,285 Reconciliation of profit or lossAdjustments and reconciling items— — — — Consolidated net income$9,932 $18,497 $9,332 $18,285 (a) The significant expense categories and amounts align with the segment-level information that is regularly provided to our chief operating decision maker.

25

Table of ContentsINSPIRE MEDICAL SYSTEMS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) (Table amounts in thousands, except share and per share amounts)

(b) Other income represents the consolidated amounts for interest and dividend income, interest expense, and other expense, net, as shown on our consolidated statements of operations and comprehensive income. For the three-month periods ended September 30, 2025 and 2024, depreciation and amortization expense was $3.7 million and $1.9 million, respectively, and for the nine-month periods ended September 30, 2025 and 2024, depreciation and amortization expense was $10.1 million and $4.1 million, respectively, and is included within the segment expense captions of cost of goods sold, research and development expense, and selling, general and administrative ("SG&A") expense. For the three-month periods ended September 30, 2025 and 2024, stock-based compensation expense was $29.